EIDD-2801, also known as Molnupiravir, is an antiviral drug developed for the treatment of viral infections, particularly those caused by RNA viruses.
The primary mechanism of action of EIDD-2801 involves inhibiting viral replication by inducing lethal mutations in the genetic material of the virus. Once metabolized into its active form, EIDD-2801 mimics one of the building blocks of RNA. When the virus attempts to replicate its genetic material using EIDD-2801, it introduces errors into its RNA sequence, leading to nonviable or less infectious viral progeny. This disruption of viral replication ultimately hampers the virus's ability to spread and cause infection.
EIDD-2801 has demonstrated broad-spectrum activity against a wide range of RNA viruses, including influenza viruses, coronaviruses (such as SARS-CoV-2), respiratory syncytial virus (RSV), and others. This broad activity makes it a promising candidate for the treatment of various viral infections.
| Technical Parameter | Value |
|---|---|
| Generic Name | EIDD-2801 (2349386-89-4) |
| Indication | Treatment of COVID-19 (Cat FIP Treatment) |
| Country of Origin | China |
| Shipping Method | Air (UPS, FedEx, TNT, EMS) or Sea |
| Shelf Life | 2 years |
| Purity | 99% |
| CAS | 2349386-89-4 |
| COA | Available |
| Molecular Weight | 329.31 g/mol |
EIDD-2801 holds promise for the treatment of viral infections, particularly in situations where there is a need for rapid response to emerging viral threats or during pandemics. Its broad-spectrum activity and ability to inhibit viral replication make it a versatile antiviral agent with potential applications in the management of infectious diseases.
1~25kgs packaging: Aluminium bag inside, Carton box outside.
25kgs packaging: Plastic bag inside, Fiber drum outside
